Articles

• Market Access: Insights from the OECD
  (Mar 23, 2010)
• Market access and HTAs: the role of ISPOR
  (Apr 20, 2010)
• GSK's approach to corporate social responsibility
  (Jun 14, 2010)
• Is value-based pricing an aid to market access?

  Leela Barham explores whether pharma firms can use value-based pricing (VBP) to improve market access.

  (Jun 16, 2010)
• Market access: How to meet both marketing authorisation and HTA needs

  Leela Barham looks at the costs and benefits of taking a more collaborative approach towards marketing authorisation and Health Technology Assessments.

  (Jul 13, 2010)
• Market access and patient access schemes

  Leela Barham explores the potential for patient access schemes (PAS) to help companies achieve market access.

  (Aug 10, 2010)
• Forecasting Europe: Whats next for forecasting?

  *In the run up to Forecasting Europe [1] in Berlin in June, eyeforpharma asked some of our key speakers for their ins* [1] http://www.eyeforpharma.com/forecastingeu/

  (May 3, 2011)
• The 'new' NHS: What does it mean for pharma?

  Leela Barham looks at the proposed reforms of the NHS in England and what they could mean for pharma’s relationship with commissioners

  (Jun 13, 2011)
• Pharma and the ‘new’ NHS: Getting the most from partnerships

  Leela Barham looks at the proposed reforms of the NHS in England and what they could mean for pharma’s approach to partnership

  (Jul 12, 2011)
• The impact of value-based pricing on market access and patience compliance

  Leela Barham explores the potential effect of value-based pricing on pharma—in the UK and beyond

  (Aug 2, 2011)
• 1
• 2
• Next
• Last

History

Member for

2 years 28 weeks